# A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

> **NCT02780141** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 75 (actual)

## Conditions studied

- ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

## Interventions

- **DRUG:** roxadustat

## Key facts

- **NCT ID:** NCT02780141
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-02
- **Primary completion:** 2017-12-12
- **Final completion:** 2017-12-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780141, "A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02780141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*